| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
108,030,000 |
| Market
Cap: |
54.46(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4901 - $1.4 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Selecta Biosciences is a clinical-stage biopharmaceutical company. Co.'s ImmTOR® platform encapsulates rapamycin, also known as sirolimus, a Food and Drug Administration approved immunomodulator, in biodegradable nanoparticles ImmTOR is designed to induce antigen-specific immune tolerance. By combining ImmTOR with antigens of interest, Co.'s immune tolerance platform restores self-tolerance to auto-antigens in autoimmune diseases, amplify the ability of biologics (including gene therapies) and mitigate the formation of anti-drug antibodies against biologic drugs.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,222,516 |
1,223,316 |
1,223,316 |
1,403,316 |
| Total Buy Value |
$688,511 |
$689,063 |
$689,063 |
$877,582 |
| Total People Bought |
1 |
1 |
1 |
3 |
| Total Buy Transactions |
12 |
13 |
13 |
15 |
| Total Shares Sold |
0 |
0 |
3,637 |
15,619 |
| Total Sell Value |
$0 |
$0 |
$3,855 |
$23,149 |
| Total People Sold |
0 |
0 |
2 |
2 |
| Total Sell Transactions |
0 |
0 |
2 |
5 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Springer Timothy A |
Director |
– • • |
2021-12-13 |
4 |
B |
$2.98 |
$43,491 |
I/I |
14,592 |
22,975,700 |
2.25 |
-71% |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2021-12-10 |
4 |
S |
$2.99 |
$12,196 |
D/D |
(4,083) |
164,381 |
|
72% |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-12-10 |
4 |
S |
$2.99 |
$51,363 |
D/D |
(17,196) |
305,255 |
|
72% |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2021-12-10 |
4 |
S |
$2.99 |
$13,053 |
D/D |
(4,370) |
199,769 |
|
72% |
|
| Johnston Lloyd P. |
Chief Operations Officer |
• – – |
2021-12-10 |
4 |
S |
$2.99 |
$13,053 |
D/D |
(4,370) |
106,715 |
|
72% |
|
| Springer Timothy A |
Director |
– • • |
2021-12-10 |
4 |
B |
$2.99 |
$175,439 |
I/I |
58,681 |
22,961,108 |
2.25 |
-72% |
|
| Springer Timothy A |
Director |
– • • |
2021-12-09 |
4 |
B |
$3.06 |
$11,468,880 |
I/I |
3,748,000 |
22,902,427 |
2.25 |
-72% |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
168,464 |
|
- |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
204,139 |
|
- |
|
| Johnston Lloyd P. |
Chief Operations Officer |
• – – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
111,085 |
|
- |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-12-08 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
322,451 |
|
- |
|
| Cox Carrie Smith |
Director |
– • – |
2021-12-03 |
4 |
B |
$2.95 |
$50,664 |
D/D |
17,200 |
82,881 |
2.39 |
-64% |
|
| Tan Kevin |
Chief Financial Officer |
• – – |
2021-12-02 |
4 |
B |
$3.03 |
$15,127 |
D/D |
5,000 |
5,000 |
2.74 |
-64% |
|
| Desilva Nishan M |
Director |
– • – |
2021-12-02 |
4 |
B |
$2.96 |
$20,723 |
D/D |
7,000 |
7,000 |
2.39 |
-64% |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-12-02 |
4 |
S |
$2.96 |
$14,065 |
D/D |
(4,746) |
284,951 |
|
64% |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-12-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,938 |
289,697 |
|
- |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2021-10-13 |
4 |
S |
$4.39 |
$15,962 |
D/D |
(3,636) |
154,714 |
|
58% |
|
| Johnston Lloyd P. |
Chief Operations Officer |
• – – |
2021-10-13 |
4 |
S |
$4.39 |
$17,086 |
D/D |
(3,892) |
97,335 |
|
58% |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-10-13 |
4 |
S |
$4.39 |
$67,224 |
D/D |
(15,313) |
278,759 |
|
58% |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2021-10-13 |
4 |
S |
$4.39 |
$17,086 |
D/D |
(3,892) |
190,389 |
|
58% |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
158,350 |
|
- |
|
| Kishimoto Takashi Kei |
Chief Scientific Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
194,281 |
|
- |
|
| Johnston Lloyd P. |
Chief Operations Officer |
• – – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
13,750 |
101,227 |
|
- |
|
| Brunn Carsten |
President and CEO |
• • – |
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
37,500 |
294,072 |
|
- |
|
| Traber Peter G |
Chief Medical Officer |
• – – |
2021-09-24 |
4 |
A |
$0.00 |
$0 |
D/D |
9,100 |
144,600 |
|
- |
|
258 Records found
|
|
Page 4 of 11 |
|
|
